The Ozempic Effect: Can Novo Nordisk Rebound? The meteoric rise and precipitous fall of Novo Nordisk's share price has left investors bewildered.
Since mid 2024, the Danish pharmaceutical giant's stock value has declined by 70%, from its position as Europe's most valuable public company.
However, beneath this tale of woe lies a more nuanced story – one of transformation and reinvention.